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Abstract
Background: Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most common cancer worldwide.
Unfortunately, the survival of patients with SCCHN has not improved in the last 40 years, and thus new targets for therapy
are needed. Recently, elevations in serum level of interleukin 6 (IL-6) and expression of Twist in tumor samples were found
to be associated with poor clinical outcomes in multiple types of cancer, including SCCHN. Although Twist has been
proposed as a master regulator of epithelial-mesenchymal transition and metastasis in cancers, the mechanisms by which
Twist levels are regulated post-translationally are not completely understood. Tumor progression is characterized by the
involvement of cytokines and growth factors and Twist induction has been connected with a number of these signaling
pathways including IL-6. Since many of the effects of IL-6 are mediated through activation of protein phosphorylation
cascades, this implies that Twist expression must be under a tight control at the post-translational level in order to respond
in a timely manner to external stimuli.
Methodology/Principal Findings: Our data show that IL-6 increases Twist expression via a transcription-independent
mechanism in many SCCHN cell lines. Further investigation revealed that IL-6 stabilizes Twist in SCCHN cell lines through
casein kinase 2 (CK2) phosphorylation of Twist residues S18 and S20, and that this phosphorylation inhibits degradation of
Twist. Twist phosphorylation not only increases its stability but also enhances cell motility. Thus, post-translational
modulation of Twist contributes to its tumor-promoting properties.
Conclusions/Significance: Our study shows Twist expression can be regulated at the post-translational level through
phosphorylation by CK2, which increases Twist stability in response to IL-6 stimulation. Our findings not only provide novel
mechanistic insights into post-translational regulation of Twist but also suggest that CK2 may be a viable therapeutic target
in SCCHN.
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Introduction
Squamous cell carcinoma of the head and neck (SCCHN) is the
seventh most common cancer worldwide [1]. Despite improve-
ments in surgical and radiation therapy techniques, the 5-year
survival rate has not improved significantly over the past several
decades and remains at 50–55%. Although local recurrence and
neck lymph node metastases account for most of the deaths from
this disease, only 10–20% of patients benefit from the integration
of systemic chemotherapeutic therapy, with marginally improved
survival and considerable toxic effects [2,3]. Therefore, new
targets for therapy are needed.
Recently, overexpression of Twist in clinical tumor specimens was
found to be correlated with metastasis and poor prognosis in patients
with SCCHN as well as other cancers [4–7]. Twist is a highly con-
served basic-helix-loop-helix transcription factor that plays an
important role in facilitating cell movement in the development of
embryos. In cancer cells, Twist is regarded as an oncogene, as its
elevated expression promotes disease progression and metastasis by
inducing the epithelial-mesenchymal transition (EMT) [8].
Despite its importance in tumor progression, post-
transcriptional regulation of Twist is not well understood
A comparative analysis of Twist mRNA and Twist protein
expression in mouse embryos showed abundant Twist RNA
expression in presomitic mesoderm, epithelial somites, and
anterior mesoderm, but no Twist protein could be found in those
tissues [9]. The discrepancy was also noted during mouse embryo
development, as Twist RNA reaches its highest level at 7.0 days
post coitum while no Twist protein could be found prior to 8.25
days post coitum. The lack of concordance between Twist mRNA
expression and Twist protein expression indicates that Twist
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transcriptional modification of transcription factors, including
phosphorylation and ubiquitination, has been shown to be
important for their function, as this provides a mechanism by
which the cell can rapidly initiate transcriptional programs in
response to external stimuli. For example, it has been reported that
Twist can be degraded through the ubiquitin/proteasome
degradation pathway, as treatment with a proteasome inhibitor
inhibits degradation of Twist [10]. There is also evidence that the
function of Twist can be modulated by phosphorylation [11,12].
Because phosphorylation is often involved in the regulation of a
protein’s ubiquitin/proteasome-dependent degradation [13], we
hypothesized that phosphorylation of Twist increases its stability
by increasing its relative expression level.
SCCHN tumorigenesis and progression are known to be
influencedby multiple growth factorsand cytokine signalingfactors,
includinginterleukin 6(IL-6)[14–17].InSCCHNpatients,elevated
serum IL-6 level correlates with poor survival and unfavorable
clinical outcome [14,15,18]. IL-6, produced either by infiltrating
immune cells or tumor cells, not only provides survival signals to
cancer cells but also facilitates motility of cancer cells through the
EMT [19,20]. The traditional IL-6 signaling pathway is through
binding with sIL-6 receptor (gp80), which induces dimerization of
gp130 and subsequent activation of either Janus kinases (JAK)/
STAT3 in a transcription-dependent manner, or the Ras-MAPK
and PI3K/Akt pathway [21]. In addition to canonical pathways,
casein kinase 2 (CK2) has also recently been reported downstream
of IL-6 signaling in cancer [22].
CK2 is a highly conserved and ubiquitously expressed serine/
threonine kinase, which consists of two catalytic (a or a’) and two b
regulatory subunits [23]. The importance of CK2 subunits can be
demonstrated by genetic studies showing that mice lacking CK2a
or CK2b are embryonic lethal while CK2 a’ knockout mice had
defects only in spermatogenesis [24–26]. CK2 has recently come
to be regarded as a ‘‘master kinase’’ since it controls the activity of
many other kinases and is involved in many important cellular
processes [27]. For example, CK2 controls the stability of IkBa
and PML tumor suppressor through phosphorylation and
modification of their ubiquitin/proteasome degradation [28,29].
CK2 has been reported to be overexpressed and to correlate with
poor survival in many tumor types, including SCCHN [30–32].
Traditionally, CK2 is regarded as a constitutively active protein
kinase, but several studies have shown that CK2 can respond to
many growth factor stimuli, including IL-6 [22,33], although the
mechanisms of its activation remain largely unclear [34].
It has been reported that STAT3, the major downstream signal of
the IL-6 pathway, can transcriptionally activate the expression of Twist
[35,36]. Our preliminary data showed, however, that Twist protein
expression was increased by IL-6 before the upregulation of Twist
mRNA in multiple aggressive SCCHN cell lines, suggesting a
transcription-independent regulation of Twist by IL-6. Since many
of the effects of IL-6 are mediated through activation of protein
phosphorylation cascades [21], and substrate phosphorylation is often
involved in regulation of a protein’s ubiquitin/proteasome2dependent
degradation [37], we postulated that Twist expression is regulated by
IL-62activated phosphorylation.
In this study, we demonstrate that treatment of SCCHN cell lines
with IL-6 leads to stabilization of the Twist protein. Further
investigation showed that IL-6 stimulates Twist phosphorylation
through activation of the CK2 serine/threonine protein kinase. Our
findings not only provide a novel mechanistic insight that Twist is
activated through phosphorylation by the CK2 kinase but also have
significant implications for the prognostication and treatment of head
and neck cancer.
Results
Twist expression is upregulated shortly after IL-6
treatment
Most SCCHN and non-small cell lung cancer (NSCLC) cell
lines secrete IL-6 and express receptors for IL-6 (Table S1 and
Figure S1) [38]. To study the impact of IL-6 on these cell lines,
Twist expression was examined along the time course of
treatment. Western blots from representative cell lines are shown
in Figure 1A. Twist expression was induced in these cells within
15 min after treatment with IL-6. In contrast, Twist mRNA levels
remained unchanged over a similar treatment period (Figure 1B).
These data indicate that Twist expression is regulated by IL-6 at
the post-transcriptional level.
This observation that IL-6 upregulates Twist expression post-
transcriptionally led us to investigate whether degradation of Twist
was in turn modulated by IL-6 treatment. The degradation rates
of Twist in SCCHN cells were examined by treating with protein
synthesis inhibitor cycloheximide (CHX) alone, CHX plus the
proteasome inhibitor MG132, or CHX plus IL-6. The amount of
protein at each time point was determined by western blot and
quantified by densitometry. As shown in Figures 1C and 1D,
endogenous Twist had a 1.2-h half-life, but when either IL-6 or
MG132 was added, less Twist was degraded and it did not reach
its half-life in the 4-h treatment period. The data are consistent
with an earlier study showing that Twist protein is degraded
through the proteasome degradation system [10] and indicate that
the Twist protein is stabilized post-translationally through
inhibition of its degradation by IL-6.
Twist is phosphorylated in response to IL-6 treatment,
and CK2 is found in the pathway between IL-6 and Twist
Because IL-6 has been shown to activate multiple cell signaling
pathways through activation of protein kinase cascades, we next
examined whether Twist is phosphorylated in response to IL-6
treatment. Cells transfected with a plasmid encoding a hemag-
glutinin (HA)-Twist fusion protein were treated with IL-6;
subsequent immunoprecipitation with an HA antibody and
western blotting using a nonspecific phosphoserine antibody
revealed increased phosphorylation of serine/threonine residues
in Twist (Figure 2A), confirming that Twist is phosphorylated in
response to IL-6 stimulation.
To identify the kinase responsible for the IL-62induced phosphor-
ylation of Twist, we used a chemical inhibitor screening strategy to
determine whether the IL-62mediated Twist upregulation can be
blocked by kinase inhibitors known to be downstream of the signaling
pathway. Twist was upregulated by IL-6 despite application of
inhibitors blocking JAK (AG490), PI-3K (Wortmannin), Erk (U0126),
p38 MAPK (SB202130), or Jun N-terminal kinase (SP600125),
indicating that Twist upregulation is independent of these pathways
(Figure 2B). Since none of the known pathways that we tested
appeared to be involved in mediating IL-62induced Twist expression,
we next scanned the amino acid sequence in the computational pro-
tein family prediction webserver http://scansite.mit.edu/motifscan_
seq.phtml and identified a CK2 substrate consensus motif (SNSE)
within Twist at residues 18 through 21 that is conserved across species
(Figure 2C).
CK2 is a serine/threonine kinase; increasing recent studies
indicate that it may play an important role in the progression of
SCCHN [32,39]. It was previously regarded as a constitutively
active intracellular kinase, but several recent findings have shown
that CK2 can be activated in response to external stimuli such as
IL-6, although the underlying mechanisms for this activation
remain unclear [22,34]. Consistent with previous studies, CK2
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inhibited by CK2-specific inhibitor 2-dimethylamino-4, 5, 6, 7-
tetrabromo-1H-benzimidazole (DMAT), as determined by a CK2
kinase activity assay that used a synthetic CK2 substrate peptide
and c-
32P-ATP as a phosphate donor (Figure 2D).
To further demonstrate that CK2 is in the pathway between IL-6
and Twist, we next examined Twist expression in the presence of IL-
6 and CK2 inhibitors DMAT or 4,5,6,7-tetrabromobenzotriazole
(TBB). As shown in Figure 2E, IL-62induced Twist expression was
inhibited by either CK2 inhibitor and this inhibition was observed
Figure 1. IL-6 upregulates Twist expression by inhibiting its degradation. (A) Twist protein expression was induced shortly after IL-6
treatment in SCCHN cells (OSC-19, HN31) and lung cancer cells (A549). After serum starvation overnight, cells were subjected to IL-6 treatment
(20 ng/ml for 0–4 h), and Twist expression in cell lysates was analyzed by western blot. b-actin was used as a loading control. (B) Twist mRNA
expression as quantified by real-time RT-PCR remained mostly unchanged throughout IL-6 treatment (0–6 hours). Values were normalized to the
expression levels of the housekeeping gene GAPDH, and are expressed as the mean fold change from basal level 6 s.e.m. For each time point, two to
four replicates were performed. All experiments were done in duplicate for each cell line. Data from a representative experiment with OSC-19 SCCHN
cells are shown. (C) Twist degradation was inhibited by either MG132 or IL-6. After OSC-19 SCCHN cells were treated with CHX (100 mM), CHX plus the
proteasome inhibitor MG132 (10 mM), or CHX plus IL-6 (20 ng/ml) for 0–4 h, Twist expression was determined by western blot. (D) The pixels in each
band in (C) were measured by Image J and normalized so that the number of pixels at time 0 was 100%. The data are plotted as the log10 of the
relative pixel density (y-axis) versus the time (min). The half-life was determined from the log of 50% relative pixel density. The half-life for Twist was
1.2 h in the presence of CHX alone and .4 h in the presence of CHX+IL-6.
doi:10.1371/journal.pone.0019412.g001
Post-Translational Regulation of Twist by IL-6
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19412across different cell lines. The effects of CK2 on IL-62induced Twist
expression were further confirmed by knockdown of the catalytic
subunit CK2a in SCCHN cell lines, in which both the basal levels of
Twist expression and those after IL-6 treatment were reduced
(Figure 2F). Taken together, these data further confirm the
importance of CK2 to IL-6–induced stabilization of Twist.
Figure 2. CK2 is in the pathway of IL-6 signaling. (A) Twist was phosphorylated in response to IL-6 treatment. OSC-19 SCCHN cells were
transfected with either the HA-Twist plasmid or control vector for 48 h, then treated with IL-6 (20 ng/ml) for 30 min; treated and untreated cell
lysates were immunoprecipitated with HA antibody and analyzed by western blot using a nonspecific phosphoserine antibody. (B) Inhibitors to
known downstream pathways of IL-6 were unable to inhibit Twist upregulation by IL-6. OSC-19 SCCHN cells were pretreated with the indicated
kinase inhibitors or dimethyl sulfoxide (DMSO; control) for 1 h, then were treated with IL-6 (20 ng/ml) for 30 min. Twist expression was determined
by western blot. (C) The CK2 phosphorylation site (SNSE) in Twist, predicted by use of http://scansite.mit.edu/motifscan_seq.phtml, is conserved
across species. (D) CK2 activity was increased by IL-6 and inhibited by CK2 inhibitor DMAT in SCCHN cells. After serum starvation overnight, lysates of
HN31 cells treated with PBS (control), IL-6 (20 ng/ml, 30 min), or IL-6 plus DMAT (10 mM) were collected. Endogenous CK2 activity in the cell lysates
(5 mg) was measured using a synthetic peptide CK2 substrate (RRRADDSDDDDD; 0.1 mM) and c-
32P-ATP as a phosphate donor as previously
described [49]. The y-axis represents the count per minute (CPM) of the radioactivity after normalizing to the no-substrate control. * P,0.05 by the
Student t-test. (E) IL-62induced Twist expression was inhibited by CK2 inhibitors. Twist expression was measured after treatment with IL-6 (30 min) in
lysates of OSC-19 SCCHN or A549 lung cancer cells previously incubated in CK2 inhibitors DMAT or TBB (1 h). Twist expression was inhibited at doses
as low as 0.8 mM and was not restricted to a specific cell line. (F) Knockdown of the catalytic subunit of CK2 (CK2a) by shRNA inhibited Twist protein
expression. Knockdown of CK2a in OSC-19 SCCHN cells for 24 h significantly reduced Twist expression and blocked its induction by IL-6 treatment
(20 ng/ml, 30 min).
doi:10.1371/journal.pone.0019412.g002
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We next examined whether CK2 and Twist are associated with
one another by using co-immunoprecipitation experiments. First
we used lysates prepared from HEK 293T cells transfected with
both wild-type Myc-Twist and CK2a. As shown in Figure 3A,
CK2a was detected in western blots of immunoprecipitates
performed with Myc antibody and Myc-Twist was detected in
the western blots of immunoprecipitates performed with CK2a
antibody. Control immunoprecipitates using nonspecific IgG did
not precipitate either protein. The data suggest that the proteins
can interact with each other. To further examine the interaction
between endogenous CK2a and Twist protein in SCCHN cells,
the FaDu cell line was chosen because it expresses a high basal
level of CK2 protein; HN31 SCCHN cells that stably express
Myc-tagged Twist (HN31 Myc-Twist SCCHN cells) were
established for immunoprecipitation purposes because of the poor
performance of the commercially available Twist antibodies. As
shown in Figure 3B, endogenous Twist in FaDu SCCHN cells was
co-immunoprecipitated with an anti-CK2a antibody. In HN31
Myc-Twist SCCHN cells, which stably express Myc-tagged Twist,
endogenous CK2a was also co-precipitated with the anti-Myc
immunoprecipitates. These data support the hypothesis that CK2
can regulate Twist by showing that these two proteins physically
associate with each other.
To examine whether the interaction between Twist and CK2a
is IL-6 dependent, co-immunoprecipitation was repeated in Myc-
Twist2stable cell line HN31 after brief treatment with IL-6
(20 min). Because HN31 expresses high levels of endogenous IL-6
(Table S1), a monoclonal antibody against the IL-6 receptor,
tocilizumab, was used to examine their interaction under blockade
Figure 3. CK2a associates with, phosphorylates, and stabilizes Twist. (A)&(B) Bi-directional co-immunoprecipitation showed that CK2a is
associated with Twist. (A)Co-immunoprecipitationwas done in lysates from HEK 293T cellstransfected with both WT Myc-TwistandCK2a.C K 2 a was co-
immunoprecipitated with Myc-Twist and vice versa. (B) Cell lysates from FaDu (left) or HN31 cells, which stably express WT Myc-Twist (right), were
immunoprecipitated with CK2a (in FaDu cells) or Myc antibody (in HN31 WT Myc-Twist cells) and subjected to western blot analysis. Endogenous Twist
wasco-immunoprecipitatedwithCK2ainFaDucelllysates,andendogenousCK2awas foundintheMyc-immunoprecipitatesofHN31Myc-WTTwistcell
lysates. (C) Co-immunoprecipitated CK2a in the HN31 Myc-Twist immunoprecipitates was increased by IL-6 (20 ng/ml, 20 min) and inhibited by
pretreatment with an antibody against IL-6 receptor, tocilizumab (50 ng/ml, 45 min). (D) CK2 phosphorylated Twist. An immunocomplex kinase assay
was performed on Myc-immunoprecipitates from HEK 293T cell lysates transiently overexpressing WT Myc-Twist or Myc -S18,20A Twist. Recombinant
CK2kinaseandc-
32P-ATPwereaddedtotheimmunoprecipitatesat30uCfor15 min,andthereactionwas stoppedbyadditionofSDS samplebufferand
heating at 95uC for 5–10 min. The samples were then subjected to electrophoresis and transferred onto a polyvinylidene fluoride membrane for
autoradiography or western blot analysis. (E) The stability of Twist was affected by site of CK2 phosphorylation.[HN31 SCCHN cells stably expressingW T
Myc-Twist, the CK2 hypophosphomimetic mutant Myc-S18,20A Twist, or the phosphorylation-mimetic mutant Myc-S18,20D Twist were treated with
CHX(100 mM)fortheindicatedtimes.Myc-Twistexpression in thecell lysates was determinedby western blot.Datarepresentone of threeindependent
experiments. The calculated half-lives (t1/2) from the triplicate experiments are expressed as mean 6 s.e.m. * P,0.05 by the Student t-test.
doi:10.1371/journal.pone.0019412.g003
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immunoprecipitated with Myc-Twist after IL-6 treatment but was
not found in the immunoprecipitates from cells pretreated with
tocilizumab for 45 min.
To determine whether CK2 phosphorylates Twist at residues
S18/S20, the putative phosphorylation site from our computa-
tional prediction, we performed an immunocomplex kinase assay
in HEK 293T cells overexpressing either wild-type (WT) Myc-
Twist or mutant Myc-Twist in which S18 and S20 are substituted
with alanine (S18,20A Twist). Purified CK2 kinase phosphorylated
WT Twist, but phosphorylation was abolished in the presence of
the CK2 inhibitor DMAT and strongly reduced in mutated
S18,20A Twist (Figure 3D).
To test whether the stability of Twist is affected by the site of
phosphorylation, stable HN31 cells overexpressing WT Twist,
S18,20A Twist, or a phosphorylation mimic in which S18 and S20
are mutated to aspartic acid (S18,20D Twist) were established.
After treating the cells with CHX, the calculated half-lives for
S18,20D Twist, S18,20A Twist, and WT Twist from the three
experiments were 9.6260.99 h for S18,20D Twist, 2.4560.59 h
for S18,20A Twist, and 4.6960.73 h for WT Twist (Figure 3E).
All P values for comparing means from any two groups with the
Student t-test were less than 0.05. This supports the hypothesis
that phosphorylation of Twist by CK2 enhances Twist stability.
Taken together, these data indicate that CK2 associates with and
phosphorylates Twist, and that phosphorylation at S18 and S20
stabilizes Twist.
CK2 and Twist are involved in IL-6–promoted cell motility
We next examined the effects of IL-6, CK2 inhibition, and Twist
knockdown on SCCHN cell motility, as measured by wound-
healing and Boyden-chamber migration assays. As shown in
Figures 4A and 4B, the migration of OSC-19 SCCHN cells in a
12-h wound-healing scratch assay was promoted by IL-6 and
suppressed by the CK2 inhibitor DMAT, while the relative
proliferation rate in each group underwent no significant change
(Figure 4C). Knockdown of Twist in OSC-19 cells profoundly
suppressed cell motility, indicating its important role in cell
migration (Figure 5A, upper panel). After treatment with IL-6 for
24 h, migration was increased, but this increase was reversed in the
Twistknockdowngroups(Figure 5A, middlepanel).IL-6–promoted
cell migration was inhibited by CK2 inhibitor as well as knockdown
of Twist, suggesting that both CK2 and Twist are implicated in
signal-induced migration. We next compared the motility of cell
lines stably expressing WT or mutant Twist in vitro. Despite the
background of high endogenous IL-6 secretion and existence of
endogenous Twist in HN31 SCCHN cells, overexpression of WT,
but not S18,20A, Twist promoted cell migration relative to the
Figure 4. CK2 is involved in IL-62promoted cell motility. (A) Images for SCCHN cell migration by wound-healing assay are shown. OSC-19
SCCHN cells were treated with PBS (control), IL-6 (20 ng/ml), DMAT (20 mM), or both IL-6 and DMAT in 2% medium as indicated. The confluent cell
monolayers were wounded by scraping with a 200-mL pipette tip. Pictures of the scratches were acquired at 0 and 12 h. (B) Quantitative
measurements of the relative migrated distance were analyzed with Image J. Data are expressed as mean 6 s.e.m. of the relative migrated distance.
* P,0.05 by the Student t-test. (C) Cell proliferation rate under each condition in (A) was measured by MTT assay for 12 h. Differences between
groups have no statistical significance.
doi:10.1371/journal.pone.0019412.g004
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pression of S18,20D Twist further increased cell motility relative to
that of cells expressing either WT or S18,20A Twist, suggesting that
this mutation leads to enhanced cell motility.
Discussion
This report demonstrates a novel post-translational phosphor-
egulation of Twist by IL-6 through activation of CK2 in SCCHN
cells. This post-translational modification can stabilize Twist,
allowing it to regulate cell motility, providing evidence of a new
mechanism for Twist regulation in cancer cells.
Published reports have implicated both Twist and IL-6 in the
development/progression of cancer, as their expressions are
detectable in many epithelial tumors or patients’ serum and are
associated with unfavorable clinical outcomes [4,16,18]. Although
it has been reported that IL-6 and its downstream signal mediator,
STAT3, can increase Twist expression through transcription in
Figure 5. IL-62induced cancer cell motility is, in part, acting through Twist. (A) Knockdown of Twist inhibited SCCHN cell migration in the
Boyden chamber migration assay. OSC-19 SCCHN cells were first transfected with control vector or Twist shRNAs for 24 h in medium with or without
IL-6 (20 ng/ml). Cells were then subjected to trypsinization, counted, and assayed for cell motility using a Boyd chamber migration assay after 20 h.
Upper & middle panels: data are expressed as mean 6 s.e.m. of the cell counts from four different lower power field microscopic views. * P,0.05 by
the Student t-test. Lower panel: Twist expression for the corresponding experiments in the upper and middle panels was detected by western blot. b-
actin was used as loading control. (B) Mutation of Twist altered migration of SCCHN cells. The motility of HN31 SCCHN cells stably expressing WT Myc-
Twist or indicated mutant Myc-Twist protein was examined with the Boyden chamber migration assay after 20 h. Upper panel: data are expressed as
mean 6 s.e.m. of the cell counts from four different lower power field microscopic views. * P,0.05 by the Student t-test. Middle panel: representative
images of the migrated cells from the corresponding transwell membranes at low power field magnification. Lower panel: western blots for the
corresponding experiments in the upper panel of (B). b-actin was used as loading control. (C) Cell proliferation of each condition in (B) as measured
by MTT assay for 20 h. Differences between groups have no statistical significance.
doi:10.1371/journal.pone.0019412.g005
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mechanism of post-translational modification of Twist expression.
As shown in Figure 2B, Twist expression is induced shortly after
IL-6 treatment despite inhibition of phospho-STAT3 by chemical
inhibitor AG490 or SB202130 at higher doses, indicating that the
Twist upregulation is STAT3 independent. As shown in Figures 1A
and 1B, Twist protein expression markedly increased before
changes in Twist mRNA expression in SCCHN cell lines. These
findings do not contradict those of an earlier study by Lo et al [36],
in which Twist protein was induced at 1 h after activation of the
EGFR-phospho-STAT3 pathway while Twist mRNA levels
increased only after 2 h of treatment. Although it was not
discussed in the earlier work, the discrepancy between Twist
mRNA and protein expression in our study indicates the existence
of a post-transcriptional regulatory mechanism across different cell
lines.
Our data demonstrate that Twist protein can be phosphorylated
and stabilized by IL-6 in SCCHN cell lines, supporting the
concept that phosphoregulation of transcriptional factors is often
utilized by multiple cellular signaling pathways for timely response
to external stimuli [37]. Although Twist phosphoregulation has
been described in studies of Twist mutations in patients with
Saethre-Chotzen syndrome, an autosomal dominant disorder of
craniosynostosis [11], the role of phosphoregulation of Twist in
cancer cells, to our knowledge, has been discussed in only a few
studies [12,40]. The CK2 phosphorylation site (S18 and S20)
identified in this study is located within the NSEEE motif, one of
five evolutionarily conserved domains in the Twist amino acid
sequence, whose function is unclear [41]. Our finding may help
improve understanding of this domain, since CK2 is connected to
many growth factor or cytokine pathways, such as IL-6 and
epidermal growth factor (EGF), in which Twist is also involved
[20,22,33,36].
Interestingly, these factors are also well known to influence
tumorigenesis and progression of SCCHN [16]. We analyzed the
post-transcriptional regulation of Twist in response to other
SCCHN-relevant cytokines/growth factors and found that the
function of stabilizing Twist is not limited to IL-6. Other
important growth factors in SCCHN, such as EGF and vascular
endothelial growth factor C, also stabilize Twist levels [Figure S2].
This suggests that a common mechanism may participate in
regulation of Twist in SCCHN, and that it may be interesting to
know the role of CK2 in these signaling pathways.
The mechanism through which CK2 is activated remains
unclear [34]. Although it has been shown that CK2 activation is
Erk-dependent in neuroblastoma cells [33], pharmacological
inhibition of Erk with U0126 in our study did not block the IL-
62mediated increase in Twist expression (Figure 2B). This
suggests that there may be cell mediators other than Erk that
can activate CK2. Whether this is cell type specific needs to be
investigated further.
Metastasis is the major threat to the health and survival of
cancer patients and its management is challenging for health care
professionals. Since Twist is regarded as a master regulator of
EMT and metastasis for cancers [8], downregulation of Twist in
cancer cells has been proposed as a promising therapeutic
approach, as it not only sensitizes cells to chemotherapy and
promotes cell apoptosis but also inhibits the cells’ migratory and
invasive abilities [33,42]. Direct targeting of Twist remains elusive,
however, as therapeutic small-interfering RNA delivery approach-
es have yet to be optimized. In this report, we show that the level
of Twist expression can be modulated by using a pharmacological
approach (i.e., a CK2 inhibitor), suggesting that CK2 could be a
useful therapeutic target. Downregulation of CK2 has been shown
to lead to reduced viability and motility in cultured SCCHN cells
and to inhibit SCCHN tumor growth and metastasis in vivo
[39,43,44]. Since many important regulatory cellular proteins are
the targets of CK2 [27], and CK2 is oncogenic in transgenic mice
[45,46], it is not surprising that CK2 has previously attracted
attention as a potential target for therapy. An oral CK2 inhibitor is
now available and is being investigated clinically [47]; further
preclinical and molecular studies are needed to define the
therapeutic potential of CK2 in SCCHN.
Materials and Methods
Cell culture, reagents, and chemical compounds
FaDu, OSC-19, and HN31 are human SCCHN cell lines. The
FaDu cell line was obtained from American Type Culture
Collection (Manassas, VA, USA); OSC-19 was purchased from
the Health Science Research Resources Bank in Japan (Sennan-
shi, Osaka, Japan); and HN31 was obtained from Dr. John Ensley
(Wayne State University, Detroit, MI, USA). A549 is a human
lung cancer cell line and was obtained from Dr. Reuben Lotan
(MD Anderson Cancer Center, Houston, TX, USA). All cells were
tested and authenticated upon receipt at the Johns Hopkins
Genetic Resources Core Facility (Baltimore, MD, USA). Unless
stated otherwise, all cells were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum (FBS),
L-glutamine, sodium pyruvate, nonessential amino acids, and a 2-
fold vitamin solution (Life Technologies Inc, Grand Island, NY,
USA). The A549 cell line was cultured in RPMI 1640
supplemented with 10% FBS. All cells were grown in a humidified
incubator at 37uC in 5% carbon dioxide. The cultures were free of
Mycoplasma species and maintained for no longer than 8 weeks
after recovery from frozen stocks. Stable HN31 cell lines
expressing WT Twist, S18,20A Twist, or S18,20D Twist were
established in the presence of 500 mg/ml of G418 (Invitrogen,
Carlsbad, CA, USA). Cycloheximide (CHX), MG132, 2-dimethy-
lamino-4, 5, 6, 7-tetrabromo-1H-benzimidazole (DMAT), 4,5,6,7-
tetrabromobenzotriazole (TBB), U0126, AG490, SB202130, and
SP600125 were purchased from EMD Chemicals (Gibbstown, NJ,
USA). Human recombinant IL-6 and CK2 kinase were purchased
from Cell Signaling Technology (Danvers, MA, USA). The CK2
substrate peptide (RRRADDSDDDDD) was synthesized by
GenScript (Piscataway, NJ, USA). Tocilizumab, a monoclonal
antibody against human IL-6 receptor, was obtained from Chugai
Pharmaceutical Co. Ltd. (Gotemba, Shizuoka, Japan).
Plasmids, antibodies, transfection, and real-time reverse-
transcription polymerase chain reaction
Short-hairpin (sh) RNAs specific for Twist were kind gifts of Dr.
Lu-Hai Wang (Mount Sinai School of Medicine, New York, NY,
USA).CK2a–CMV (clone id: 3908058, catalog number: MHS1010-
9205500) and shRNAs specific for CK2a (NM_001895) (catalog
numbers: RHS3979-9593435, RHS3979-98490747) were purchased
from Open Biosystems (Huntsville, AL, USA). Myc-Twist
(NM_000474) was cloned into pcDNA3.1+ using BamH1/EcoR1
and standard polymerase chain reaction (PCR) procedures. Point
mutations were introduced by PCR using the QuikChange site
mutagenesis kit following the manufacturer’s protocol (Stratagene,
Cedar Creek, TX, USA). Antibodies recognizing Twist-1 and
CK2a were purchased from Cell Signaling Technology. Transfec-
tion in HEK 293T was carried out by using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. Trans-
fection in OSC-19 and HN31 was carried out with the Amexa
Necleofector System (Lonza, Switzerland) programs V-020 and
T-001, respectively. Relative quantities of mRNA expression were
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Hercules, CA, USA) with the primers described previously
(36;38). SYBR green fluorescence dye (Thermo-Scientific, Worces-
ter, MA, USA) was used in the study.
Western blot analysis, immunoprecipitation, and CK2
kinase activity assay
Western blot analysis and immunoprecipitation were done as
previously described [48]. For Myc and b-actin, the protein bands
were detected by LI-COR imaging system (LI-COR Bioscience,
Lincoln, NE, USA). Chemiluminescence was used to detect all
other antibodies. The CK2 kinase activity assay was performed as
described previously [49]. Briefly, the cell lysates were collected in
hypo-osmotic buffer after treatment with PBS (control) or IL-6
(20 ng/ml) for 20 min, and the cell lysates (5 mg), synthetic peptide
CK2 substrate (RRRADDSDDDDD; 0.1 mM), and c-
32P-ATP in
the assay dilution buffer were incubated for 10 min at 30uC. The
phosphorylated substrate was then separated on P81 phospho-
cellulose paper and quantified with a scintillation counter.
Boyd chamber migration assay and wound-healing assay
The transwell migration assay was performed over a 20-h
period using 24-well Boyden chamber system plates from BD
Biosciences (San Jose, CA, USA). Cells that had migrated across
the filters were counted using Image J software. The wound-
healing assay was done as described previously [50].
Statistical analysis
The Student t-test was used for all statistical analyses, and a P
value less than 0.05 was considered statistically significant.
Supporting Information
Figure S1 Expression of the receptor for IL-6 (IL-6R) in
SCCHN cells. The levels of IL-6R mRNA expression were
normalized to the expression levels of the housekeeping gene
GAPDH and were expressed as the mean fold change from basal 6
s.e.m. Because there is no detectable mRNA expression in cell
lines HOK16B and Nom 9, all expression levels were normalized
to that of SQCCY1. All experiments were done in triplicate for
each cell line. (* P,0.05)
(TIF)
Figure S2 Not only IL-6 but also EGF and VEGF-C can
upregulate Twist expression in SCCHN cells. Twist
protein expression was induced shortly after IL-6 (20 ng/ml),
EGF (20 ng/ml) or VEGF-C (50 ng/ml) in OSC-19 SCCHN
cells. Twist protein expression in cell lysates after indicated
treatment was analyzed by western blot; b-actin was used as a
loading control.
(TIF)
Table S1 Levels of secreted IL-6 in SCCHN cell lines.
Levels of secreted IL-6 in the supernatants of cultured SCCHN
cells were determined by using a human IL-6 ELISA kit after cells
were cultured in 2% complete medium for 48 h. Data are
expressed as pg/million cells 6 s.e.m. All of the SCCHN lines
secreted increased levels of IL-6 relative to the immortalized
human keratinocye cell line (NOM 9).
(EPS)
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